Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
This study has been completed.
Study NCT00081874 Information provided by M.D. Anderson Cancer Center
First Received: April 23, 2004 Last Updated: September 29, 2006
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Mantle Cell Lymphoma
Myelofibrosis
Additional conditions recognized in this trial
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid
Leukemia, T-Cell
Lymphoma
Lymphoma, Mantle-Cell
Metaplasia
Myeloid Metaplasia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Myeloproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Splenic Diseases
Interventions listed in this trial
RAD001
Additional drug interventions recognized in this trial
Everolimus
More general drug interventions related to this trial
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
M.D. Anderson Cancer Center
Novartis
Back to top of Main Content
